Clinical trials: Dendritic Cell
Metastatic Malignant Melanoma
Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
In this trial the investigators want to combine chemotherapy with immunotherapy by giving the patients Temozolomide, before vaccination. The investigators have also included hTERT and survivin mRNA in the vaccine.
- Trial name
- NCT00961844
- Testing
- Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion, Temozolomide
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Steinar Aamdal
HLA-A2 Positive Cells Present, Refractory Melanoma
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to…
- Trial name
- NCT04093323
- Testing
- Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Extensive-stage Small Cell Lung Cancer
Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer
This is a single-arm Phase Ib/II multicenter open-label study, with translational sub-study, of atezolizumab plus autologous dendritic cell vaccine as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- VENEZO-LUNG (NCT04487756)
- Testing
- Atezolizumab 1200 mg in 20 ML Injection, ADC Vaccine, Carboplatin
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Instituto Oncológico Dr Rosell
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Ovarian Cancer, Advanced Epithelial Ovarian Cancer
A Phase 1 Study of Cellgram-DC in Patients With Advanced or Recurrent Epithelial Ovarian Cancer
The goal of this clinical trial was to evaluate the safety of Cellgram-DC, an autologous dendritic cell-based cancer immunotherapy, in patients with advanced or recurrent epithelial ovarian cancer.
- Conditions
- Ovarian Cancer, Advanced Epithelial Ovarian Cancer, Recurrent Epithelial Cancer of Ovary
- Trial name
- NCT04614051
- Testing
- Cellgram-DC
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Pharmicell Co., Ltd.
Glioblastoma Multiforme, Glioblastoma
Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)
Purposes: The purpose of this phase-II clinical trial is to determine whether or not ADCTA-G, a biologic "vaccine" preparation of patient's own dendritic cell (DC) for glioblastoma multiforme (GBM) treatment, is safe and…
- Trial name
- NCT02772094
- Testing
- Single arm, open-label
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- China Medical University Hospital
Non-small Cell Lung Cancer
MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer
MIDRIXNEO-LUNG is a novel autologous dendritic cell vaccine for non-small cell lung cancer patients, targeting neoantigens predicted from the patient-individual tumor's mutanome.
- Trial name
- MIDRIXNEO (NCT04078269)
- Testing
- Dendritic cell immunotherapy, Antigen-specific DTH, Control DTH
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- University Hospital, Ghent
Endometrial Cancer, Cancer of Endometrium
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Background: Endometrial cancer (EC) of the uterus is becoming more common in the US. Sometimes EC often has increased levels of a protein called HER2. Cancers with HER2 tend to be more aggressive and have poorer outcomes.
- Conditions
- Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
- Trial name
- NCT06253494
- Testing
- AdHER2DC vaccine, Pembrolizumab, N-803
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Sclerosis
A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial
A first-in-human clinical trial to treat patients with multiple sclerosis by vaccination with tolerogenic dendritic cells (tolDC), generated using Good Manufacturing Practice (GMP) will be conducted.
- Trial name
- MS-tolDC (NCT02618902)
- Testing
- tolerogenic dendritic cells (tolDC)
- Where
- Belgium
- Volunteers
- 9 people
- Sponsor
- University Hospital, Antwerp
Stage IV Gastric Cancer
Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer
The purpose of this study is to evaluate the clinical safety and preliminary efficacy of antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene in the…
- Trial name
- AAV-DC-CTL (NCT01637805)
- Testing
- Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
The goal of this clinical trial is to evaluate clinical efficacy of incorporating Epcoritamab into the salvage treatment routine for relapsed-refractory aggressive B-cell lymphoma, followed by autologous stem-cell transplantation…
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, DLBCL, Nos Genetic Subtypes
- Trial name
- NCT06287398
- Testing
- Epcoritamab
- Where
- Australia
- Volunteers
- 39 people
- Sponsor
- Australasian Leukaemia and Lymphoma Group
Prostate Cancer
MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer
The purpose of this study is to determine the effectiveness of a drug called Poly-ICLC, also known as HiltonolTM, in boosting the body's immune system's response to an experimental vaccine therapy (called the MUC-1 vaccine).
- Trial name
- NCT00374049
- Testing
- MUC_1
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Olivera Finn
Soft Tissue Sarcoma
External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma
This is a Phase II study using a combination of external beam radiation with intratumoral injection of dendritic cells (white blood cells) as neo-adjuvant treatment for patients with high-risk soft tissue sarcoma.
- Trial name
- NCT00365872
- Testing
- Dendritic Cell (DC) Injections, Radiation therapy, Complete Resection - Surgery for tumor removal
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Malignant Melanoma Stage IV
Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients
The purpose of this study is to determine whether the combination of chemotherapy (Cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.
- Trial name
- NCT00722098
- Testing
- DC Vaccine & Cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Baylor Research Institute
Chidamide, R-CHOP Chemotherapy
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
- Conditions
- Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL)
- Trial name
- NCT06891157
- Testing
- Chidamide plus R-CHOP
- Where
- China
- Volunteers
- 148 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a…
- Conditions
- Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
- Trial name
- CombiCoR-Vax (NCT06522919)
- Testing
- Autologous Dendritic Cell (DC) Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Breast Cancer, Metastatic Breast Cancer
Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients
This pilot clinical trial studies the safety of a dendritic cell vaccine when given with gemcitabine hydrochloride in treating patients with breast cancer that has spread beyond the breast and local lymph nodes to other organs in…
- Trial name
- NCT02479230
- Testing
- tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Joseph Baar, MD, PhD
HCV Infection
Study of the Role of Dendritic Cells in the Recurrence of Hepatitis C After Liver Transplantation. Analysis of Hepatitis C Virus (HCV) Quasispecies Evolution.
Re-infection of the liver graft occurs universally following liver transplantation for HCV-induced end stage liver disease. Interestingly, the manifestation of HCV infection ranging from an asymptomatic carrier state to rapid…
- Trial name
- NCT00213707
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Epithelial Ovarian Cancer
Ovarian Cancer Vaccine for Patients in Remission
The purpose of this study is to determine the safety and efficacy of an investigational therapeutic agent (Cvac) in ovarian cancer patients in first or second remission and to determine its ability to prevent cancer from…
- Trial name
- NCT01068509
- Testing
- Cvac
- Where
- 18 sites in United States, Australia
- Volunteers
- 63 people
- Sponsor
- Prima BioMed Ltd
Malignant Glioma
Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma
Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis carries with it a median survival of approximately 24 months.
- Trial name
- NCT01792505
- Testing
- Dendritic Cell Vaccine in combination with Imiquimod cream
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Cedars-Sinai Medical Center